LORRI BALLARD: Open Payments
NPI 1124717434 · ARLINGTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,952 in 120 payments from 16 companies in 2025. Trend: 2023 $22 · 2024 $2,149 · 2025 $2,952
Food & beverage: $2,952
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 37 | $723 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 28 | $606 |
| Janssen Pharmaceuticals, Inc | 15 | $462 |
| Otsuka America Pharmaceutical, Inc. | 12 | $348 |
| E.R. Squibb & Sons, L.L.C. | 5 | $203 |
| Supernus Pharmaceuticals, Inc. | 1 | $125 |
| Alkermes, Inc. | 4 | $117 |
| Axsome Therapeutics, Inc. | 4 | $91 |
| Lundbeck LLC | 5 | $89 |
| Vanda Pharmaceuticals Inc. | 2 | $51 |
Products named: VRAYLAR, CAPLYTA, REXULTI, INVEGA SUSTENNA, COBENFY, Qelbree, ARISTADA, Auvelity.
Industry payments across TX — which companies pay providers there.
